Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selective estrogen receptor modulators: the ideal estrogen replacement?(2)(2).

M J. Sexton1, R B. Gherman

  • 1Department of OB/GYN, Division of Maternal/Fetal Medicine, Portsmouth Naval Hospital, Portsmouth, Virginia, USA

Primary Care Update for Ob/Gyns
|February 13, 2001
PubMed
Summary

Selective estrogen receptor modulators (SERMs) show promise for hormone replacement therapy. These agents may reduce breast cancer risk, improve bone density, and protect against heart disease with fewer side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Group A streptococcal pharyngitis.

Primary care update for Ob/Gyns·2020
Same journal

Acute bronchitis: a review of diagnosis and evidence-based management.

Primary care update for Ob/Gyns·2020
Same journal

Interferon therapy in primary care.

Primary care update for Ob/Gyns·2001
Same journal

Conservative management of urinary incontinence in women.

Primary care update for Ob/Gyns·2001
Same journal

Borderline ovarian tumors.

Primary care update for Ob/Gyns·2001
Same journal

Child occupant protection: a summary of current safety recommendations.

Primary care update for Ob/Gyns·2001

Area of Science:

  • Endocrinology
  • Oncology
  • Cardiology
  • Bone Health

Background:

  • Estrogen replacement therapy aims to benefit skeletal, cardiovascular, and central nervous systems while minimizing uterine and breast side effects.
  • Selective estrogen receptor modulators (SERMs) are being investigated as alternatives to traditional hormone therapy.

Purpose of the Study:

  • To evaluate the potential of SERMs, like tamoxifen and raloxifene, as ideal estrogen replacement therapy options.
  • To assess the efficacy of SERMs in reducing breast cancer risk, improving bone mineral density, and offering cardiovascular protection.

Main Methods:

  • Review of studies on SERMs, including tamoxifen and raloxifene.
  • Analysis of their effects on bone mineral density, lipid metabolism, and cardiovascular markers.

Related Experiment Videos

  • Comparison of uterine and breast side effect profiles, particularly raloxifene's antagonistic effect on the endometrium.

    • Main Results:

    • SERMs demonstrate potential in reducing breast carcinoma risk.
    • These agents have shown efficacy in increasing bone mineral density and preventing osteoporosis.
    • Favorable effects on lipid metabolism suggest a protective role against coronary heart disease and myocardial infarction.

    Conclusions:

    • Raloxifene, unlike tamoxifen, acts as an estrogen antagonist in the endometrium, avoiding adverse uterine side effects.
    • Ongoing trials like the Study of Tamoxifen and Raloxifene and Raloxifene Use for the Heart are crucial for determining SERMs' suitability for postmenopausal women.